Tweet
J Virol Methods. 2017 Jan 17. pii: S0166-0934(16)30584-5. doi: 10.1016/j.jviromet.2017.01.008. [Epub ahead of print]
Evaluation of multiplex assay platforms for detection of influenza hemagglutinin subtype specific antibody responses influenza HA subtype specific antibody detection platform.
Li ZN1, Weber KM2, Limmer RA2, Horne BJ2, Stevens J3, Schwerzmann J2, Wrammert J4, McCausland M4, Phipps AJ2, Hancock K3, Jernigan DB3, Levine M3, Katz JM5, Miller JD3.
Author information
Abstract
Influenza hemagglutination inhibition (HI) and virus microneutralization assays (MN) are widely used for seroprevalence studies. However, these assays have limited field portability and are difficult to fully automate for high throughput laboratory testing. To address these issues, three multiplex influenza subtype-specific antibody detection assays were developed using recombinant hemagglutinin antigens in combination with Chembio, Luminex?, and ForteBio? platforms. Assay sensitivity, specificity, and subtype cross-reactivity were evaluated using a panel of well characterized human sera. Compared to the traditional HI, assay sensitivity ranged from 87% to 92% and assay specificity in sera collected from unexposed persons ranged from 65% to 100% across the platforms. High assay specificity (86-100%) for A(H5N1) rHA was achieved for sera from exposed or unexposed to hetorosubtype influenza HAs. In contrast, assay specificity for A(H1N1)pdm09 rHA using sera collected from A/Vietnam/1204/2004 (H5N1) vaccinees in 2008 was low (22-30%) in all platforms. Although cross-reactivity against rHA subtype proteins was observed in each assay platform, the correct subtype specific responses were identified 78% to 94% of the time when paired samples were available for analysis. These results show that high throughput and portable multiplex assays that incorporate rHA can be used to identify influenza subtype specific infections.
Published by Elsevier B.V.
KEYWORDS:
Antibody; Antibody biosensor assay; Chembio; Hemagglutinin; Influenza; Luminex(?)
PMID: 28108183 DOI: 10.1016/j.jviromet.2017.01.008
[PubMed - as supplied by publisher]
Evaluation of multiplex assay platforms for detection of influenza hemagglutinin subtype specific antibody responses influenza HA subtype specific antibody detection platform.
Li ZN1, Weber KM2, Limmer RA2, Horne BJ2, Stevens J3, Schwerzmann J2, Wrammert J4, McCausland M4, Phipps AJ2, Hancock K3, Jernigan DB3, Levine M3, Katz JM5, Miller JD3.
Author information
Abstract
Influenza hemagglutination inhibition (HI) and virus microneutralization assays (MN) are widely used for seroprevalence studies. However, these assays have limited field portability and are difficult to fully automate for high throughput laboratory testing. To address these issues, three multiplex influenza subtype-specific antibody detection assays were developed using recombinant hemagglutinin antigens in combination with Chembio, Luminex?, and ForteBio? platforms. Assay sensitivity, specificity, and subtype cross-reactivity were evaluated using a panel of well characterized human sera. Compared to the traditional HI, assay sensitivity ranged from 87% to 92% and assay specificity in sera collected from unexposed persons ranged from 65% to 100% across the platforms. High assay specificity (86-100%) for A(H5N1) rHA was achieved for sera from exposed or unexposed to hetorosubtype influenza HAs. In contrast, assay specificity for A(H1N1)pdm09 rHA using sera collected from A/Vietnam/1204/2004 (H5N1) vaccinees in 2008 was low (22-30%) in all platforms. Although cross-reactivity against rHA subtype proteins was observed in each assay platform, the correct subtype specific responses were identified 78% to 94% of the time when paired samples were available for analysis. These results show that high throughput and portable multiplex assays that incorporate rHA can be used to identify influenza subtype specific infections.
Published by Elsevier B.V.
KEYWORDS:
Antibody; Antibody biosensor assay; Chembio; Hemagglutinin; Influenza; Luminex(?)
PMID: 28108183 DOI: 10.1016/j.jviromet.2017.01.008
[PubMed - as supplied by publisher]